C3A細(xì)胞 
	
		是否是腫瘤細(xì)胞:	1
	
	
		物種來源:	人
	
	
		運(yùn)輸方式:	凍存運(yùn)輸
	
	
		細(xì)胞形態(tài):	上皮樣
	
	
		數(shù)量:	大量
	
	
		生長(zhǎng)狀態(tài):	貼壁生長(zhǎng)
	
	
		年限:	15 years adolescent
	
	
		ATCC Number:	CRL-10741?
	
	
		C3A細(xì)胞器官來源:	肝
	
	
		相關(guān)**:	肝癌
	
	
		Designations:	C3A [HepG2/C3A, derivative of Hep G2 (ATCC HB-8065)]
	
	
		Depositors:	 Baylor College of Medicine
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: liver
	
	
		Disease: C3A細(xì)胞hepatocellular carcinoma
	
	
		Cellular Products:	alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen;
	
	
		complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein)
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Applications:	transfection host
	
	
		Tumorigenic:	No
	
	
		DNA Profile (STR):	Amelogenin: X,Y
	
	
		CSF1PO: 10,11
	
	
		D13S317: 9,13
	
	
		D16S539: 12,13
	
	
		D5S818: 11,13
	
	
		C3A細(xì)胞D7S820: 10
	
	
		THO1: 9
	
	
		TPOX: 8,9
	
	
		vWA: 17
	
	
		Age:	15 years adolescent
	
	
		Gender:	male
	
	
		Ethnicity:	Caucasian
	
	
		Comments:	C3A is clonal derivative of Hep G2 that was selected for strong contact inhibition of growth, high albumin production, high production of alpha fetoprotein (AFP) and ability to grow in glucose deficient medium.
	
	
		As the cells become confluent, there is a marked reduction in AFP secretion and an increase in albumin secretion.
	
	
		Gluconeogenesis activity is strongly oxgen dependent.
	
	
		The cells have nitrogen metabolizing activity comparable to perfused rat livers.
	
	
		There is no evidence of a Hepatitis B virus genome in this cell line.
	
	
		Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Temperature: C3A細(xì)胞37.0°C
	
	
		Subculturing:	Protocol:
	
	
		Remove and discard culture medium.
	
	
		Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
	
	
		Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
	
	
		Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
	
	
		Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
	
	
		Add appropriate aliquots of the cell suspension to new culture vessels.
	
	
		Incubate cultures at 37?C.
	
	
		
	
	
		Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
	
	
		Medium Renewal: Twice per week
	
	
		Preservation:	Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
	
	
		Storage temperature: liquid nitrogen vapor phase
	
	
		Related Products: C3A細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
	
	
		recommended serum:ATCC 30-2020
	
	
		parental cell line:ATCC HB-8065
	
	
		References:	22052: Kelly JH. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). US Patent 5,290,684 dated Mar 1 1994